Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 18, Issue 1, 2003, Pages 65-75

  Creed, T J ^a   Norman, M R ^a   Probert, C S J ^a   Harvey, R F ^b   Shaw, I S ^b   Smithson, J ^c   Anderson, J ^d   Moorghen, M ^a   Gupta, J ^a   Shepherd, N A ^e   Dayan, C M ^a   Hearing, S D ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

^b FRENCHAY HOSPITAL   (United Kingdom)

^c SOUTHMEAD HOSPITAL   (United Kingdom)

^d CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

^e GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BASILIXIMAB; DEXAMETHASONE; HYDROCORTISONE; INTERLEUKIN 2 RECEPTOR; MESALAZINE; PREDNISOLONE; RECEPTOR BLOCKING AGENT; STEROID;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; FEVER; HUMAN; HUMAN CELL; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; LETHARGY; LOW BACK PAIN; LYMPHOCYTE; MALE; MOON FACE; OPEN STUDY; OUTCOMES RESEARCH; PARESTHESIA; PHOTOSENSITIVITY; PILOT STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RECTUM BIOPSY; RELAPSE; REMISSION; SCORING SYSTEM; SIDE EFFECT; ULCERATIVE COLITIS; ULCERATIVE COLITIS SYMPTOM SCORE; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

ADULT; AGED; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; DRUG COMBINATIONS; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; REMISSION INDUCTION; STEROIDS; TREATMENT OUTCOME;

EID: 10744232542     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01639.x     Document Type: Article

References (43)

1. Chakravarty B. Predictors and the rate of medical treatment failure in ulcerative colitis. Am J Gastroenterol 1993; 88: 852-5.
2. Travis S, Farrant J, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-10.
3. Hyde GM, Thillainayagam AV. Jewell DP. Intravenous cyclosporine as rescue therapy in severe ulcerative colitis: time for a reappraisal? Eur J Gastroenterol Hepatol 1998; 10(5): 411-3.
4. Van Gossum A, Schmit A, Adler M, et al. Short and long term efficacy of cyclosporin administration in patients with acute severe ulcerative colitis. Acta Gastroenterol Belg 1997; 60: 197-200.
5. Carbonnel F, Boruchowicz A, Duclos B, et al. Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses. Dig Dis Sci 1996; 41: 2471-6.
6. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120(6): 1323-9.
7. Truelove S, Willoughby C, Lee E, Kettlewell M. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978; 2: 1086-8.
8. Hearing S, Norman M, Smyth C, Foy C, Dayan C. Wide variation in lymphocyte steroid sensitivity among healthy human volunteers. J Clin Endocrinol Metab 1999; 84: 4149-54.
9. Hearing S, Norman M, Probert C, Haslam N, Dayan C. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut 1999; 45: 382-8.
10. Alvarez J, Surs W, Leung L, Ikle D, Gefland E, Szefler S. Steroid resistant asthma: immunological and pharmacological features. J Allergy Clin Immunol 1992; 89: 714-21.
11. Seki M, Ushiyama C, Seta N, et al. Apoptosis of lymphocytes induced by glucocorticoids and relationship to therapeutic efficacy in patients with systemic lupus erythematosus. Arthritis Rheumatol 1998; 41: 823-30.
12. Langhoff E, Ladefoged J, Jakobsen B, et al. Recipient lymphocyte sensitivity to methylprednisolone affects cadaver kidney graft survival. Lancet 1986; 1: 1296-7.
13. Walker K, Potter J, House A. Interleukin-2 synthesis in the presence of steroids: a model of steroid resistance. Clin Exp Immunol 1987; 68: 162-7.
14. Kam J, Szefler S, Surs W, Sher E, Leung L. Combination of IL-2 and IL-4 reduces glucocorticoid receptor binding affinity and T-cell response to glucocorticoids. J Immunol 1993; 151: 3460-6.
15. Irusen E, Mathews J, Takahashi A, Barnes P, Chung K, Adcock I. p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 2002; 109: 649-57.
16. Nashan B, Moore R, Amlot P, Schmidt A, Abeywikrama K, Soulillou J. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193-8.
17. Mulloy L. Wright F. Hall M, Moore M. Basiliximab reduces acute cellular rejection in renal allografts from cadaveric and living donors. Transplant Proc 1999; 31: 1210-3.
18. Kovarik JM, Rawlings E, Sweny P, et al. Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation. Transplant Proc 1996; 28(2): 913-4.
19. Kovarik JM, Kahan BD, Rajagopalan PR, et al. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group. Transplantation 1999: 68(a): 1228-9.
20. Schroeder K, Tremaine W, Ilstrup D. Coated oral 5-amino-salicylic acid therapy for mild to moderately active ulcerative colitis. N Engl J Med 1987; 317: 1625-8.
21. Baron J, Connell A, Lennard-Jones J. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964; 1: 89-92.
22. Truelove S, Witts L. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955; 2: 1041-8.
23. Matl I, Bachleda P, Lao M, et al. Safety and efficacy of an alternative basiliximab (Simulect) regimen after renal transplantation: administration of a single 40-mg dose on the first postoperative day in patients receiving triple therapy with azathioprine. Transpl Int 2003; 16(1): 45-52.
24. Irvine E. A quality of life index for inflammatory bowel disease. Can J Gastroenterol 1993; 7: 155-9.
25. Riley S. Mani V, Goodman M, Dutt S, Herd M. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32: 174-8.
26. Onrust S, Wiseman L. Basiliximab. Drugs 1999; 57: 207-13.
27. Cheung W, Garratt AM, Russel IT, Williams JG. The UK IBDQ - A British version of the inflammatory bowel disease questionnaire: development and validation. J Clin Epidemiol 2000; 53: 297-306.
28. Probert C, Hearing S, Schreiber S. et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003; 52: 997-1001.
29. Bell HK, Parslew RA. Use of basiliximab as a cyclosporin-sparing agent in palmoplantar pustular psoriasis with myalgia as an adverse effect. Br J Dermatol 2002; 147(3): 606-7.
30. Salim A, Emerson RM, Dalziel KL. Successful treatment of severe generalized pustular psoriasis with basiliximab (interleukin-2 receptor blocker). Br J Dermatol 2000; 143(5): 1121-2.
31. Kagi MK, Heyer G. Efficacy of basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in a patient with severe chronic atopic dermatitis. Br J Dermatol 2001; 145(2): 350-1.
32. Owen CM, Harrison PV. Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody. Clin Exp Dermatol 2000; 25(3): 195-7.
33. Berman JA, Patel K, Caro J. Enhanced response to basiliximab in a patient with aplastic anemia after treatment with standard immunosuppression. Am J Hematol 2002; 71(1): 64.
34. Barros VR, Rocha V, Garcia VD, Garcia CD. Anaphylactic shock after retreatment with basiliximab. Transpl Proc 2003; 35(1): 579.
35. Blam M, Stein R, Lichtenstein G. Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Am J Gastroenterol 2002; 96: 1977-97.
36. Van Assche G, Dalle I, Noman M, et al. A pilot study on the use of the humanised anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 2003; 98: 369-76.
37. Honda M, Orii F, Ayabe T, et al. Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology 2000; 118: 859-66.
38. Bantel H, Domschke W, Schulze-Osthoff K. Molecular mechanisms of glucocorticoid resistance. Gastroenterology 2000; 119: 1178-9.
39. Ellery J, Nicholls P. Alternate signalling pathways from the interleukin-2 receptor. Cytokine Growth Factor Rev 2002; 13: 27-30.
40. Stocklin E, Wissler M. Gouilleux F, Groner B. Functional interactions between stat5 and the glucocorticoid receptor. Nature 1996; 383: 726-8.
41. Biola A, Lefebvre P, Perrin-Wolff M, Sturm M, Bertoglio J, Pallardy M. Interleukin-2 inhibits glucocorticoid receptor transcriptional activity through a mechanism involving Stat5 (signal transducer and activator of transcription 5) but not AP-1. Mol Endocrinol 2001; 15: 1062-76.
42. Jamieson C, Yamamoto K. Crosstalk pathway for inhibition of glucocorticoid-induced apoptosis by T-cell receptor signalling. Proc Natl Acad Sci USA 2000; 97: 7319-24.
43. Rogatsky I, Logan S, Garabedian M. Antagonism of glucocorticoid receptor transcriptional activation by the c-Jun N-terminal kinase. Proc Natl Acad Sci USA 1998; 95: 2050-5.